Key Points of Assay Design and Quality Control for Thyroid Cancer Panel Product Development

Target region and site selection in panel design

The design of a thyroid cancer panel should not simply involve stacking the number of genes. Site selection needs to balance sensitivity and specificity while also accommodating nucleic acid extraction requirements across different sample types, such as fresh tissue, formalin-fixed paraffin-embedded tissue, and fine-needle aspiration eluate. Common design approaches include point mutation detection regions, fusion gene breakpoint regions, and hotspot regions in promoter regions. Each site is generally required to have sufficient sequencing depth to ensure that low-frequency variants can be reliably identified. The detection scope should be reasonably planned by taking into account the pathological type composition of thyroid cancer, population mutation spectrum characteristics, and the coverage of existing targeted drugs.

Quality control points in the testing workflow

From nucleic acid extraction, library construction, and sequencing to data analysis, any step may affect the final result. Laboratories typically set up negative and positive controls to monitor inter-batch stability. For paraffin samples, attention needs to be paid to the impact of fixation time and storage conditions on nucleic acid quality. The bioinformatics workflow in the data analysis step needs to have the capability for variant filtering, false-positive exclusion, and fusion gene detection, and an internal database should be established for background noise monitoring. Both kits and laboratory-developed methods need to undergo validation and compliance management in accordance with relevant regulations for medical devices or laboratory-developed tests.

Report specifications and physician-patient communication

Test reports should clearly indicate sample information, testing methods, covered regions, variant results, and explanations of their clinical significance, and should avoid absolute wording that may cause misunderstanding. For variants of uncertain significance, the report should note the level of evidence and recommend subsequent judgment in combination with multidisciplinary consultation. In physician-patient communication, testing personnel and clinicians need to explain to patients the purpose of testing, possible result types, and limitations, so that patients understand that molecular testing is an auxiliary decision-making tool rather than a promise of therapeutic efficacy.

Compliance development and industry trends

With the improvement of regulations related to in vitro diagnostic reagent registration management, the registration pathway for tumor-related gene panels is gradually becoming clearer. Companies need to pay attention to the review requirements for companion diagnostics, the setting of performance evaluation indicators, and reference material design. At the same time, the standardization of database construction and bioinformatics analysis capabilities is also advancing. Future thyroid cancer panels are expected to continue improving in terms of requiring less sample input, shorter turnaround time, and standardized report interpretation, providing clinical practice with a more stable auxiliary reference tool.